MedTrace Logo

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-09-13

No results posted yet for this study

Summary

The purpose of this study is to make Domperidone available to patients with gastrointestinal disorders who have failed standard therapy and who might benefit from it.

Conditions

Interventions

DRUG

Domperidone

Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.

Sponsors & Collaborators

  • Carle Physician Group

    lead INDIV

Principal Investigators

  • Andrew Batey, M.D. · Carle Health Care Incorporated d/b/a Carle Physician Group

  • Anna Keck, PhD · Carle Foundation Hospital

  • James Dougherty, MD · Carle Foundation Hospital

  • Eugene Greenberg, MD · Carle Physician Group

  • Vicki Shah, PA · Carle Physician Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761254 on ClinicalTrials.gov